<http://webisa.webdatacommons.org/417866595>	<http://www.w3.org/ns/prov#value>	"Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1) or any cancer curatively treated > 3 years prior to study entry" .
<http://webisa.webdatacommons.org/prov/120224230>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/417866595> .
<http://webisa.webdatacommons.org/417866595>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/464198207>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/417866595> .
<http://webisa.webdatacommons.org/prov/466595157>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/417866595> .
<http://webisa.webdatacommons.org/417866595>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<clinicaltrials.gov> .